How I manage a patient with MRSA bacteraemia

Area of Science:

• Infectious Diseases
• Clinical Microbiology
• Pharmacology

Background:

• Staphylococcus aureus bloodstream infections (SAB) are prevalent with high mortality (15-25%).
• Methicillin-resistant S. aureus (MRSA) bloodstream infections constitute 10-40% of SAB cases, exhibiting even higher mortality rates.
• Limited robust evidence exists for optimal SAB management, leading to practice variations.

Observation:

• This case study details the management of MRSA bacteraemia with a primary bone and joint infection.
• Key decision points in patient management are explored, including empirical and directed antibiotic choices.
• The discussion emphasizes a real-world, case-based approach to complex MRSA infections.

Findings:

• Prioritizes randomized clinical trial data for recommendations, supplemented by author expertise where RCTs are unavailable.
• Addresses critical aspects: empirical and directed antibiotic selection for MRSA, vancomycin monitoring, combination therapy for persistent bacteraemia, and oral switch strategies.
• Highlights the need for individualized treatment plans over algorithmic approaches for heterogeneous MRSA bacteraemia.

Implications:

• Aggressive source control and appropriate antibiotic selection/duration are crucial for MRSA bacteraemia.
• A tailored, patient-specific management strategy is often necessary due to the heterogeneity of MRSA bacteraemia.
• Further randomized controlled trials are essential to enhance the evidence base for managing MRSA bacteraemia.